BRCA2 and ovarian carcinoma: A similar likelihood of progression-free survival was shown after five years in a large cohort of women with FIGO stage III or IV epithelial ovarian cancer (Bookman et al. 2009) but these studies did not take BRCA1/BRCA2 mutation status into account.